Elan Gorshein, DO, JD, MPH
Assistant Professor of Medicine (Hematology)Cards
About
Research
Publications
2025
Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin
Albano F, Browning S, Li F, Bar N, Parker T, Anderson T, Stevens E, VanOudenhove J, Matthews M, Gorshein E, Haldas J, Talsania A, Sabbath K, Seropian S, Halene S, Perna F, Neparidze N. Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin. Blood 2025, 146: 7578. DOI: 10.1182/blood-2025-7578.Peer-Reviewed Original ResearchBCMA-targeted therapyBelantamab mafodotinPhase I partRelapsed/refractory myelomaClinical responseStable diseasePartial responseCombination therapyMedian ageMultiple myelomaImmune profileT cellsBone marrowB cellsDay 1PD1+ T cellsAssociated with clinical responseMedian age of patientsCD19+ B cellsFlow cytometryI partCombination of elotuzumabImmune combination therapyInferior clinical responsePhase Ib/II trialOptimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma
Huang A, Sequeira N, Zhang A, de Matos U, Gorshein E, Dosani T, Vankina R, Ali S, Neparidze N, Kumar S. Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma. Blood 2025, 146: 4567. DOI: 10.1182/blood-2025-4567.Peer-Reviewed Original ResearchSkeletal-related eventsBone-modifying agentsInternational Myeloma Working GroupInternational Myeloma Working Group guidelinesIncidence of skeletal-related eventsBone-modifying agent administrationBone-modifying agent treatmentMultiple myelomaRadiation to boneRelapsed/refractory MM patientsAcademic cancer centerDiagnosis of MMProportion of patientsYears of followGuideline adherenceDental screeningMM patientsDental clearanceMedian ageFirst dosePathological fracturesSignificant morbidityNewly-diagnosedPrescribing practicesRetrospective studyNewly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management
Yasar F, Gorshein E. Newly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management. Advances In Hematology 2025, 2025: 6622365. PMID: 41048839, PMCID: PMC12494473, DOI: 10.1155/ah/6622365.Peer-Reviewed Original ResearchHigh-risk cytogenetic abnormalitiesAutologous stem cell transplantationHigh-risk MMMinimal residual diseaseMultiple myelomaChimeric antigen receptor T cellsHigh-risk multiple myelomaBispecific antibodiesAssociated with aggressive diseaseInferior progression-freeCAR-T cellsStem cell transplantationTransplant-ineligible patientsRisk-adapted approachHeterogeneous hematologic malignancyStandard of careProgression-FreeResidual diseaseCAR-TInduction regimensCytogenetic abnormalitiesFrontline therapyMaintenance therapyOverall survivalAggressive disease
2024
Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchRelapsed/Refractory Multiple MyelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related qualityPrevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Peer-Reviewed Original Research
2023
Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population
Traore K, Taneja A, Gorshein E, Castro F, Derkach A, Martinez J, Serrano E, Lesokhin A, Ahlstrom J, Block T, Hydren J, Usmani S, Shah U. Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population. Blood 2023, 142: 7363. DOI: 10.1182/blood-2023-186913.Peer-Reviewed Original ResearchBody mass indexPlasma cell disordersHigher HEI scoresFood frequency questionnaireGeneral US populationHEI scoresDietary patternsTotal fruit consumptionMultiple myelomaUS populationDietary interventionDietary guidelinesFruit consumptionCell disordersHealthy dietBlock Food Frequency QuestionnaireElevated body mass indexLower body mass indexCancer-specific mortalityLong-term outcomesHealthy Eating IndexNutrition Examination SurveyHealthy dietary habitsRole of nutritionOlder age groups“Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation
Chen P, Gorshein E, Tormey C, Siddon A, Perincheri S. “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation. American Journal Of Hematology 2023, 98: 984-988. PMID: 36688500, DOI: 10.1002/ajh.26856.Peer-Reviewed Educational Materials
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic valueUse of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center
Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.Peer-Reviewed Original ResearchBone-modifying agentsUse of denosumabYale Cancer CenterZoledronic acidMultiple myelomaMM patientsCancer CenterMedian numberPhysician preferenceCommon reasonClinical practiceNew fracturesNuclear factor kappa-B ligandStudy periodApproval of denosumabEfficacy of denosumabIncidence of SREsMain treatment centreSmilow Cancer HospitalSuppress bone turnoverPatient's renal functionBone resorption markersCohort of patientsGlomerular filtration rateDate of diagnosis
2019
Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience
Krakora R, Shih W, Popli P, Gorshein E, Salaru G, David K, Bannerji R. Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience. Blood 2019, 134: 5071. DOI: 10.1182/blood-2019-129390.Peer-Reviewed Original ResearchProgression-free survivalAllogeneic stem cell transplantAcute lymphoblastic leukemiaTime of diagnosisAchievement of CRBetter overall survivalOverall survivalComplete remissionInsurance statusAcute myeloblastic leukemiaSurvival outcomesLymphoblastic leukemiaRegeneron PharmaceuticalsHealth insuranceSurvival rateSingle comprehensive cancer centerBetter progression-free survivalWorse progression-free survivalProportional hazards regression methodsPhiladelphia chromosome statusSingle-center experienceRetrospective chart reviewStem cell transplantComprehensive cancer centerLack of insurance
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
HIC ID2000032539RoleSub InvestigatorPrimary Completion Date05/19/2029Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
HIC ID2000031290RoleSub InvestigatorPrimary Completion Date03/31/2027Recruiting ParticipantsGenderMaleAge18+ yearsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting Participants
Clinical Care
Overview
Elan Gorshein, DO (doctor of osteopathic medicine), MPH, specializes in treating patients with hematologic malignancies at Smilow Cancer Hospital.
Hematologic malignancies are cancers that begin in blood-forming tissue, such as bone marrow and immune system cells, and include leukemia, lymphoma, and multiple myeloma. Osteopathic medicine focuses on treating the patient as a whole rather than addressing specific symptoms.
Dr. Gorshein has a JD (juris doctor) degree and is an assistant professor of clinical medicine (hematology) at Yale School of Medicine.
Clinical Specialties
Hematologic Oncology; Thoracic Oncology
Fact Sheets
Thrombocytopenia
Learn More on Yale MedicineCOVID-19
Learn More on Yale MedicineCoronavirus
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale Medicine
Yale Medicine News
News
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.